NASDAQ:MNKD

MannKind - MNKD Stock Forecast, Price & News

$3.09

+0.10 (+3.34%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.00
▼
$3.22
50-Day Range: $2.99
▼
$4.35
52-Week Range: $2.49
▼
$5.44

Volume: 4.28 million shs
Average Volume: 5.35 million shs
Market Capitalization: $780.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

MannKind MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 94.2% Upside
$6.00 Price Target
Short Interest: Bearish
13.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.99
Based on 6 Articles This Week
Insider Trading: Acquiring Shares
$53,033 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.38) to ($0.13) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

720th out of 1,093 stocks

Pharmaceutical Preparations Industry

346th out of 547 stocks

3.5

Analyst's Opinion

Consensus Rating
MannKind has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, MannKind has a forecasted upside of 94.2% from its current price of $3.09.
Amount of Analyst Coverage
MannKind has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
13.03% of the float of MannKind has been sold short.
Short Interest Ratio / Days to Cover
MannKind has a short interest ratio ("days to cover") of 6.9.
Change versus previous month
Short interest in MannKind has recently increased by 0.19%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
MannKind does not currently pay a dividend.
Dividend Growth
MannKind does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MNKD.

2.8

News and Social Media Coverage

News Sentiment
MannKind has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for MannKind this week, compared to 3 articles on an average week.
Search Interest
Only 5 people have searched for MNKD on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MannKind insiders have bought 22.03% more of their company's stock than they have sold. Specifically, they have bought $53,033.00 in company stock and sold $43,458.00 in company stock.
Percentage Held by Insiders
Only 2.30% of the stock of MannKind is held by insiders.
Percentage Held by Institutions
46.83% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for MannKind are expected to grow in the coming year, from ($0.38) to ($0.13) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MannKind is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MannKind is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About MannKind (NASDAQ:MNKD) Stock

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MNKD Stock News Headlines

September 29, 2022 | investorplace.com

7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up - InvestorPlace

September 29, 2022 | finance.yahoo.com

When Can We Expect A Profit From MannKind Corporation (NASDAQ:MNKD)?

September 25, 2022 | nasdaq.com

Even though MannKind Corporation's (NASDAQ:MNKD) stock is down 14% this week, insiders who bought lately made a US$64k profit - Nasdaq

September 24, 2022 | nasdaq.com

Even though MannKind Corporation's (NASDAQ:MNKD) stock is down 14% this week, insiders who bought lately made a US$64k profit

September 22, 2022 | streetinsider.com

MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference - StreetInsider.com

September 21, 2022 | globenewswire.com

MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference - GlobeNewswire

September 21, 2022 | benzinga.com

MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference - MannKind (NASD - Benzinga

September 21, 2022 | finance.yahoo.com

MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference

September 19, 2022 | investorplace.com

7 Penny Stocks with Buy Ratings to Keep Your Eye On - InvestorPlace

September 9, 2022 | nasdaq.com

Interesting MNKD Call Options For October 28th

September 9, 2022 | finance.yahoo.com

A number of insiders bought MannKind Corporation (NASDAQ:MNKD) stock last year, which is great news for shareholders - Yahoo Finance

September 8, 2022 | finance.yahoo.com

A number of insiders bought MannKind Corporation (NASDAQ:MNKD) stock last year, which is great news for shareholders

September 8, 2022 | seekingalpha.com

MNKD stock gains on Phase 1 data for lung disease candidate (NASDAQ:MNKD) - Seeking Alpha

September 6, 2022 | seekingalpha.com

Mannkind to further advance lung disease candidate after positive Phase 1 data

September 6, 2022 | markets.businessinsider.com

MannKind Shares Fall After Completing Initial Stage Lung Disease Study

September 6, 2022 | globenewswire.com

Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine - GlobeNewswire

September 6, 2022 | finance.yahoo.com

Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine

September 1, 2022 | seekingalpha.com

Mannkind Corporation Stock: Ready For Your Biotech Portfolio (NASDAQ:MNKD) - Seeking Alpha

September 1, 2022 | globenewswire.com

MannKind Corporation to Participate in the H.C. Wainwright - GlobeNewswire

September 1, 2022 | finance.yahoo.com

MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

August 28, 2022 | reuters.com

MNKD.OQ - MannKind Corporation | Stock Price & Latest News | Reuters

August 23, 2022 | finance.yahoo.com

$9.3 Billion Worldwide Rapid Acting Insulin Industry to 2027 - Featuring Adocia, Biocon Limited and Geropharm Among Others - Yahoo Finance

August 19, 2022 | finance.yahoo.com

Analysts Are Betting On MannKind Corporation (NASDAQ:MNKD) With A Big Upgrade This Week

August 11, 2022 | globenewswire.com

Zealand Pharma Announces Financial Results for the First Half of 2022 - GlobeNewswire

August 10, 2022 | nasdaq.com

Despite Lacking Profits AVEO Pharmaceuticals (NASDAQ:AVEO) Seems To Be On Top Of Its Debt - Nasdaq

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MNKD Company Calendar

Last Earnings: 8/09/2022
Today: 10/01/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:MNKD
CUSIP: 56400P20
CIK: 899460
Web: www.mannkindcorp.com
Phone: (818) 661-5000
Fax: 661-775-2081
Employees: 348
Year Founded: 1991

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +94.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-80,930,000.00
Net Margins: -133.37%
Pretax Margin: -133.37%
Return on Equity: N/A
Return on Assets: -32.06%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.25
Quick Ratio: 2.90

Sales & Book Value

Annual Sales: $75.44 million
Price / Sales: 10.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.83) per share
Price / Book: -3.72

Miscellaneous

Outstanding Shares: 252,570,000
Free Float: 246,756,000
Market Cap: $780.44 million
Optionable: Optionable
Beta: 1.74

Social Links

Key Executives

Dr. Michael E. Castagna Pharm.D. (Age 45)
CEO & Director
Comp: $1.12M

Mr. Steven B. Binder (Age 59)
Chief Financial Officer
Comp: $772.05k

Mr. Joseph Kocinsky M.B.A. (Age 58)
M.S., Chief Technology Officer
Comp: $608.75k

Dr. David B. Thomson (Age 55)
Exec. VP, Gen. Counsel & Sec.
Comp: $772.9k

Dr. Stuart A. Tross Ph.D. (Age 55)
Chief People & Workplace Officer
Comp: $652.85k

Mr. Thomas Hofmann M.D.
Ph.D., Chief Scientific Officer

Ms. Rosabel Realica Alinaya (Age 61)
VP of Investor Relations & Treasury

Mr. John F. Bedard (Age 72)
Sr. VP of Worldwide Regulatory Affairs

Mr. James Patrick McCauley Jr. (Age 56)
J.D., M.B.A., Chief Commercial Officer

Mr. Alejandro Galindo M.B.A. (Age 50)
M.S., Exec. VP of Endocrine Bus. Unit

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MNKD Stock - Frequently Asked Questions

Should I buy or sell MannKind stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MNKD shares.
View MNKD analyst ratings or view top-rated stocks.
What is MannKind's stock price forecast for 2022?: 3 Wall Street analysts have issued twelve-month price objectives for MannKind's stock. Their MNKD share price forecasts range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 94.2% from the stock's current price.
View analysts price targets for MNKD or view top-rated stocks among Wall Street analysts.
How have MNKD shares performed in 2022?: MannKind's stock was trading at $4.37 on January 1st, 2022. Since then, MNKD shares have decreased by 29.3% and is now trading at $3.09.
View the best growth stocks for 2022 here.
When is MannKind's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our MNKD earnings forecast.
How were MannKind's earnings last quarter?: MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. The biopharmaceutical company had revenue of $18.90 million for the quarter, compared to analyst estimates of $15.62 million. The business's revenue was down 18.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.05) EPS.

What other stocks do shareholders of MannKind own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).
What is MannKind's stock symbol?: MannKind trades on the NASDAQ under the ticker symbol "MNKD."
How do I buy shares of MannKind?: Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is MannKind's stock price today?: One share of MNKD stock can currently be purchased for approximately $3.09.
How much money does MannKind make?: MannKind (NASDAQ:MNKD) has a market capitalization of $780.44 million and generates $75.44 million in revenue each year. The biopharmaceutical company earns $-80,930,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.
How many employees does MannKind have?: The company employs 348 workers across the globe.
How can I contact MannKind?: MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for the company is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081.

This page (NASDAQ:MNKD) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MannKind - MNKD Stock Forecast, Price & News

MannKind MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows